Chemo and radiation to keep the bladder in recurrent bladder cancer
Part of Cancer, Kidney & urinary, Women’s health & pregnancy clinical trials.
This study looks at a treatment plan that uses a combination of chemotherapy and radiation to try to cure bladder cancer without removing the bladder. It is for people who have had bladder cancer come back several times or who did not get good results from BCG treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a type of bladder cancer that has not reached the deep muscle layer (called non-muscle invasive).
- The tumor has come back at least 2 times after surgery, or the standard medicine put into the bladder (BCG) did not work or caused bad side effects.
- You have chosen not to remove the bladder and want a treatment that tries to keep it.
- You are 18 years or older and feel well enough to be active (score 0-2 on a standard scale).
- Your body's organs (blood, liver, kidneys) are healthy enough to handle chemo and radiation.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study watches people with muscle-invasive bladder cancer who choose to keep their bladder after receiving neoadjuvant therapy (treatment before the main treatment). It aims to see how well bladder-preserving treatments like chemoradiation work over time.
This study tests a combination of bladder-sparing treatments for muscle-invasive bladder cancer, including surgery, chemotherapy, immunotherapy, and radiation, followed by maintenance immunotherapy. The goal is to see if this approach can control cancer while preserving the bladder, compared to a watch-and-wait approach.
This trial tests a combination of chemotherapy and immunotherapy to treat large, non-invasive bladder cancer before and after surgery. It aims to avoid removing the bladder while still effectively treating the cancer.
This trial tests whether radiation therapy can help people with early-stage bladder cancer that has a high risk of coming back. It may be an option for those who have not tried BCG treatment.
This study tests a medication called nimotuzumab (a type of targeted therapy) added to standard chemoradiation (chemotherapy plus radiation) to treat muscle-invasive bladder cancer without surgically removing the bladder. The goal is to control the cancer while preserving the bladder.
This study tests a combination of two chemotherapy drugs, mitomycin-C and gemcitabine, given directly into the bladder for people with high-risk bladder cancer that hasn't been controlled with BCG therapy. It's an option for those who can't or don't want to have their bladder removed.
Hear when a new High - Risk NMIBC trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.